Emami Limited
Emami Limited (EMAMILTD.NS) Stock Competitors & Peer Comparison
See (EMAMILTD.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Household & Personal Products Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EMAMILTD.NS | ₹393.10 | -4.23% | 171.6B | 21.62 | ₹18.18 | +3.05% |
| HINDUNILVR.BO | ₹2,075.00 | -2.85% | 4.9T | 44.87 | ₹46.24 | +2.07% |
| HINDUNILVR.NS | ₹2,074.40 | -2.83% | 4.9T | 48.11 | ₹43.12 | +2.07% |
| GODREJCP.BO | ₹1,008.90 | -2.99% | 1T | 56.65 | ₹17.81 | +1.98% |
| GODREJCP.NS | ₹1,008.70 | -2.97% | 1T | 56.60 | ₹17.82 | +1.98% |
| MARICO.BO | ₹743.25 | -1.45% | 962.7B | 56.31 | ₹13.20 | +1.41% |
| MARICO.NS | ₹742.45 | -1.50% | 961.7B | 56.29 | ₹13.19 | +1.41% |
| DABUR.BO | ₹419.70 | -2.66% | 744.4B | 40.47 | ₹10.37 | +1.91% |
| DABUR.NS | ₹419.60 | -2.65% | 744.2B | 40.38 | ₹10.39 | +1.91% |
| COLPAL.BO | ₹1,877.55 | -2.21% | 510.7B | 38.41 | ₹48.88 | +2.72% |
Stock Comparison
EMAMILTD.NS vs HINDUNILVR.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, HINDUNILVR.BO has a market cap of 4.9T. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while HINDUNILVR.BO trades at ₹2,075.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas HINDUNILVR.BO's P/E ratio is 44.87. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HINDUNILVR.BO's ROE of +0.29%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HINDUNILVR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HINDUNILVR.BO's competition here
EMAMILTD.NS vs HINDUNILVR.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, HINDUNILVR.NS has a market cap of 4.9T. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while HINDUNILVR.NS trades at ₹2,074.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas HINDUNILVR.NS's P/E ratio is 48.11. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HINDUNILVR.NS's ROE of +0.29%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HINDUNILVR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HINDUNILVR.NS's competition here
EMAMILTD.NS vs GODREJCP.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, GODREJCP.BO has a market cap of 1T. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while GODREJCP.BO trades at ₹1,008.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas GODREJCP.BO's P/E ratio is 56.65. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GODREJCP.BO's ROE of +0.15%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GODREJCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GODREJCP.BO's competition here
EMAMILTD.NS vs GODREJCP.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, GODREJCP.NS has a market cap of 1T. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while GODREJCP.NS trades at ₹1,008.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas GODREJCP.NS's P/E ratio is 56.60. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GODREJCP.NS's ROE of +0.15%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GODREJCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GODREJCP.NS's competition here
EMAMILTD.NS vs MARICO.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, MARICO.BO has a market cap of 962.7B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while MARICO.BO trades at ₹743.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas MARICO.BO's P/E ratio is 56.31. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to MARICO.BO's ROE of +0.40%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to MARICO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check MARICO.BO's competition here
EMAMILTD.NS vs MARICO.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, MARICO.NS has a market cap of 961.7B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while MARICO.NS trades at ₹742.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas MARICO.NS's P/E ratio is 56.29. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to MARICO.NS's ROE of +0.40%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to MARICO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check MARICO.NS's competition here
EMAMILTD.NS vs DABUR.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, DABUR.BO has a market cap of 744.4B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while DABUR.BO trades at ₹419.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas DABUR.BO's P/E ratio is 40.47. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to DABUR.BO's ROE of +0.17%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to DABUR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check DABUR.BO's competition here
EMAMILTD.NS vs DABUR.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, DABUR.NS has a market cap of 744.2B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while DABUR.NS trades at ₹419.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas DABUR.NS's P/E ratio is 40.38. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to DABUR.NS's ROE of +0.17%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to DABUR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check DABUR.NS's competition here
EMAMILTD.NS vs COLPAL.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, COLPAL.BO has a market cap of 510.7B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while COLPAL.BO trades at ₹1,877.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas COLPAL.BO's P/E ratio is 38.41. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to COLPAL.BO's ROE of +0.81%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to COLPAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check COLPAL.BO's competition here
EMAMILTD.NS vs COLPAL.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, COLPAL.NS has a market cap of 510.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while COLPAL.NS trades at ₹1,877.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas COLPAL.NS's P/E ratio is 38.48. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to COLPAL.NS's ROE of +0.81%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to COLPAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check COLPAL.NS's competition here
EMAMILTD.NS vs PGHH.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, PGHH.BO has a market cap of 298.2B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while PGHH.BO trades at ₹9,187.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas PGHH.BO's P/E ratio is 41.51. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PGHH.BO's ROE of +1.01%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to PGHH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PGHH.BO's competition here
EMAMILTD.NS vs PGHH.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, PGHH.NS has a market cap of 296.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while PGHH.NS trades at ₹9,138.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas PGHH.NS's P/E ratio is 41.52. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PGHH.NS's ROE of +1.01%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to PGHH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PGHH.NS's competition here
EMAMILTD.NS vs GILLETTE.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, GILLETTE.BO has a market cap of 243.4B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while GILLETTE.BO trades at ₹7,471.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas GILLETTE.BO's P/E ratio is 45.63. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GILLETTE.BO's ROE of +0.58%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GILLETTE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GILLETTE.BO's competition here
EMAMILTD.NS vs GILLETTE.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, GILLETTE.NS has a market cap of 243.4B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while GILLETTE.NS trades at ₹7,471.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas GILLETTE.NS's P/E ratio is 45.66. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GILLETTE.NS's ROE of +0.58%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GILLETTE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GILLETTE.NS's competition here
EMAMILTD.NS vs EMAMILTD.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, EMAMILTD.BO has a market cap of 172.1B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while EMAMILTD.BO trades at ₹394.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas EMAMILTD.BO's P/E ratio is 21.68. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to EMAMILTD.BO's ROE of +0.29%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to EMAMILTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check EMAMILTD.BO's competition here
EMAMILTD.NS vs CUPID.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, CUPID.NS has a market cap of 113.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while CUPID.NS trades at ₹84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas CUPID.NS's P/E ratio is 136.53. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to CUPID.NS's ROE of +0.24%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to CUPID.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check CUPID.NS's competition here
EMAMILTD.NS vs CUPID.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, CUPID.BO has a market cap of 113.7B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while CUPID.BO trades at ₹84.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas CUPID.BO's P/E ratio is 136.37. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to CUPID.BO's ROE of +0.24%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to CUPID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check CUPID.BO's competition here
EMAMILTD.NS vs HONASA.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, HONASA.NS has a market cap of 97B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while HONASA.NS trades at ₹298.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas HONASA.NS's P/E ratio is 62.66. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HONASA.NS's ROE of +0.13%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HONASA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HONASA.NS's competition here
EMAMILTD.NS vs HONASA.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, HONASA.BO has a market cap of 97B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while HONASA.BO trades at ₹298.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas HONASA.BO's P/E ratio is 62.64. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HONASA.BO's ROE of +0.13%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HONASA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HONASA.BO's competition here
EMAMILTD.NS vs JYOTHYLAB.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, JYOTHYLAB.NS has a market cap of 74.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while JYOTHYLAB.NS trades at ₹203.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas JYOTHYLAB.NS's P/E ratio is 21.90. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JYOTHYLAB.NS's ROE of +0.18%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to JYOTHYLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JYOTHYLAB.NS's competition here
EMAMILTD.NS vs JYOTHYLAB.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, JYOTHYLAB.BO has a market cap of 74.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while JYOTHYLAB.BO trades at ₹203.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas JYOTHYLAB.BO's P/E ratio is 21.92. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JYOTHYLAB.BO's ROE of +0.18%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to JYOTHYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JYOTHYLAB.BO's competition here
EMAMILTD.NS vs BAJAJCON.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, BAJAJCON.NS has a market cap of 45.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while BAJAJCON.NS trades at ₹350.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas BAJAJCON.NS's P/E ratio is 30.03. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to BAJAJCON.NS's ROE of +0.22%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to BAJAJCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check BAJAJCON.NS's competition here
EMAMILTD.NS vs BAJAJCON.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, BAJAJCON.BO has a market cap of 45.7B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while BAJAJCON.BO trades at ₹350.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas BAJAJCON.BO's P/E ratio is 30.09. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to BAJAJCON.BO's ROE of +0.22%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to BAJAJCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check BAJAJCON.BO's competition here
EMAMILTD.NS vs SHK.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, SHK.NS has a market cap of 16.5B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while SHK.NS trades at ₹119.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas SHK.NS's P/E ratio is 9.71. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to SHK.NS's ROE of +0.13%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to SHK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check SHK.NS's competition here
EMAMILTD.NS vs ALLTIME.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, ALLTIME.NS has a market cap of 12.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while ALLTIME.NS trades at ₹196.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas ALLTIME.NS's P/E ratio is 36.09. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to ALLTIME.NS's ROE of +0.08%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to ALLTIME.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check ALLTIME.NS's competition here
EMAMILTD.NS vs BCLIND.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, BCLIND.NS has a market cap of 7.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while BCLIND.NS trades at ₹26.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas BCLIND.NS's P/E ratio is 6.73. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to BCLIND.NS's ROE of +0.14%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to BCLIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check BCLIND.NS's competition here
EMAMILTD.NS vs KAYA.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, KAYA.BO has a market cap of 3.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while KAYA.BO trades at ₹250.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas KAYA.BO's P/E ratio is -4.40. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to KAYA.BO's ROE of +0.62%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to KAYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check KAYA.BO's competition here
EMAMILTD.NS vs KAYA.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, KAYA.NS has a market cap of 3.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while KAYA.NS trades at ₹249.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas KAYA.NS's P/E ratio is -4.40. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to KAYA.NS's ROE of +0.62%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to KAYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check KAYA.NS's competition here
EMAMILTD.NS vs ADORMUL.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, ADORMUL.BO has a market cap of 1.3B. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while ADORMUL.BO trades at ₹135.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas ADORMUL.BO's P/E ratio is -29.80. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to ADORMUL.BO's ROE of -0.32%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to ADORMUL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check ADORMUL.BO's competition here
EMAMILTD.NS vs PCCOSMA.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, PCCOSMA.BO has a market cap of 849.3M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while PCCOSMA.BO trades at ₹320.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas PCCOSMA.BO's P/E ratio is 10.59. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PCCOSMA.BO's ROE of +0.16%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to PCCOSMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PCCOSMA.BO's competition here
EMAMILTD.NS vs JHS.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, JHS.BO has a market cap of 604M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while JHS.BO trades at ₹6.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas JHS.BO's P/E ratio is -7.59. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JHS.BO's ROE of -0.03%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to JHS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JHS.BO's competition here
EMAMILTD.NS vs JHS.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, JHS.NS has a market cap of 593.2M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while JHS.NS trades at ₹6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas JHS.NS's P/E ratio is -11.00. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JHS.NS's ROE of -0.03%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to JHS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JHS.NS's competition here
EMAMILTD.NS vs STDSFAC.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, STDSFAC.BO has a market cap of 405.3M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while STDSFAC.BO trades at ₹49.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas STDSFAC.BO's P/E ratio is N/A. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to STDSFAC.BO's ROE of N/A. Regarding short-term risk, EMAMILTD.NS is less volatile compared to STDSFAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check STDSFAC.BO's competition here
EMAMILTD.NS vs AMBICAAGAR.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, AMBICAAGAR.BO has a market cap of 386M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while AMBICAAGAR.BO trades at ₹22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas AMBICAAGAR.BO's P/E ratio is 77.48. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to AMBICAAGAR.BO's ROE of +0.01%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to AMBICAAGAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check AMBICAAGAR.BO's competition here
EMAMILTD.NS vs AMBICAAGAR.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, AMBICAAGAR.NS has a market cap of 385.1M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while AMBICAAGAR.NS trades at ₹22.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas AMBICAAGAR.NS's P/E ratio is 30.30. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to AMBICAAGAR.NS's ROE of +0.01%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to AMBICAAGAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check AMBICAAGAR.NS's competition here
EMAMILTD.NS vs NKIND.NS Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, NKIND.NS has a market cap of 372.5M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while NKIND.NS trades at ₹61.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas NKIND.NS's P/E ratio is -6.02. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to NKIND.NS's ROE of +0.02%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to NKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check NKIND.NS's competition here
EMAMILTD.NS vs NKIND.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, NKIND.BO has a market cap of 363.6M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while NKIND.BO trades at ₹60.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas NKIND.BO's P/E ratio is -5.87. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to NKIND.BO's ROE of +0.02%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to NKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check NKIND.BO's competition here
EMAMILTD.NS vs NUWAY.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, NUWAY.BO has a market cap of 354.6M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while NUWAY.BO trades at ₹37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas NUWAY.BO's P/E ratio is 14.40. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to NUWAY.BO's ROE of N/A. Regarding short-term risk, EMAMILTD.NS is more volatile compared to NUWAY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check NUWAY.BO's competition here
EMAMILTD.NS vs PAOS.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, PAOS.BO has a market cap of 298.3M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while PAOS.BO trades at ₹48.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas PAOS.BO's P/E ratio is -9.24. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PAOS.BO's ROE of +0.22%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to PAOS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PAOS.BO's competition here
EMAMILTD.NS vs SATTVASUKU.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, SATTVASUKU.BO has a market cap of 264.7M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while SATTVASUKU.BO trades at ₹0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas SATTVASUKU.BO's P/E ratio is -69.00. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to SATTVASUKU.BO's ROE of +0.12%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to SATTVASUKU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check SATTVASUKU.BO's competition here
EMAMILTD.NS vs PARMCOS-B.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, PARMCOS-B.BO has a market cap of 163.9M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while PARMCOS-B.BO trades at ₹33.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas PARMCOS-B.BO's P/E ratio is 160.71. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PARMCOS-B.BO's ROE of +0.00%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to PARMCOS-B.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PARMCOS-B.BO's competition here
EMAMILTD.NS vs HIPOLIN.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, HIPOLIN.BO has a market cap of 154.2M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while HIPOLIN.BO trades at ₹49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas HIPOLIN.BO's P/E ratio is -4.92. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HIPOLIN.BO's ROE of -0.35%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to HIPOLIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HIPOLIN.BO's competition here
EMAMILTD.NS vs CORNE.BO Comparison April 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 171.6B. In comparison, CORNE.BO has a market cap of 46.8M. Regarding current trading prices, EMAMILTD.NS is priced at ₹393.10, while CORNE.BO trades at ₹9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 21.62, whereas CORNE.BO's P/E ratio is -5.51. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to CORNE.BO's ROE of +0.16%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to CORNE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check CORNE.BO's competition here